

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Cloprostenol Formulation

Other means of identification : ESTRUMATE® (A002698)  
ESTRUMATE SYNTHETIC PROSTAGLANDIN FOR CATTLE  
AND HORSES (36076)

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Veterinary product

Recommended restrictions : Not applicable  
on use

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person : EHSDATASTEWARD@msd.com  
responsible for the SDS

#### 1.4 Emergency telephone number

1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008)**  
Not a hazardous substance or mixture.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008)**  
No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

#### **Additional Labelling**

EUH210 Safety data sheet available on request.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Benzyl alcohol	100-51-6 202-859-9 603-057-00-5	Acute Tox. 4; H302 Acute Tox. 4; H332 Eye Irrit. 2; H319  Acute toxicity estimate  Acute oral toxicity: 1,620 mg/kg	>= 1 - < 10
Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3 259-439-3	Resp. Sens. 1; H334 Repr. 1B; H360F STOT SE 1; H370 (Lungs) STOT RE 1; H372 (Ovary)	< 0.1

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- Protection of first-aiders : No special precautions are necessary for first aid responders.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R*), 3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3	TWA	0.01 ug/m <sup>3</sup> (OEB 5)	Internal
Further information: RSEN, Skin				
		Wipe limit	0.1 ug/100 cm <sup>2</sup>	Internal

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m <sup>3</sup>
		Inhalation	Acute systemic effects	110 mg/m <sup>3</sup>
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day
		Skin contact	Acute systemic effects	40 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	5.4 mg/m <sup>3</sup>
		Inhalation	Acute systemic effects	27 mg/m <sup>3</sup>
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
		Skin contact	Acute systemic effects	20 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4 mg/kg bw/day
		Ingestion	Acute systemic effects	20 mg/kg bw/day

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

Substance name	Environmental Compartment	Value
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0.1 mg/l
	Intermittent use/release	2.3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5.27 mg/kg
	Marine sediment	0.527 mg/kg
	Soil	0.456 mg/kg

### 8.2 Exposure controls

#### Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to I.S. EN 14387

Filter type : Organic vapour type (A)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state : Aqueous solution

Colour : clear

Odour : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	5.6 - 6.1 (20 - 25 °C)
Viscosity	:	
Viscosity, kinematic	:	No data available
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	No data available
Relative density	:	1
Density	:	No data available
Relative vapour density	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

### 9.2 Other information

Explosives	:	Not explosive
------------	---	---------------

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : None known.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Calculation method

#### Components:

**Benzyl alcohol:**



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

Acute oral toxicity : LD50 (Rat): 1,620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4.178 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Acute oral toxicity : LD50 (Rat): > 25 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): > 50 mg/kg  
Application Route: Subcutaneous

LD50 (Rat): > 50 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 5 mg/kg  
Application Route: Intravenous  
Remarks: No mortality observed at this dose.

LD50 (Mouse): 350 mg/kg  
Application Route: Intramuscular

LD50 (Mouse): 54.7 mg/kg  
Application Route: Intravenous

TDLo (Monkey): 0.0025 - 0.025 mg/kg  
Application Route: Intramuscular  
Target Organs: Lungs  
Symptoms: Diarrhoea, Vomiting, Rapid respiration

TDLo (Monkey): 0.0013 mg/kg  
Application Route: Intramuscular  
Target Organs: ovaries

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

#### **Benzyl alcohol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Remarks : Not classified due to lack of data.  
Can be absorbed through skin.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

---

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Benzyl alcohol:**

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : Irritation to eyes, reversing within 21 days

##### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Remarks : Not classified due to lack of data.

### Respiratory or skin sensitisation

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### Components:

##### **Benzyl alcohol:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative

##### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Result : Sensitiser

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### **Benzyl alcohol:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: mouse lymphoma cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: equivocal

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intraperitoneal  
Result: negative

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Benzyl alcohol:**

Species : Mouse  
Application Route : Ingestion  
Exposure time : 103 weeks  
Method : OECD Test Guideline 451  
Result : negative

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Remarks : Not classified due to lack of data.

### **Reproductive toxicity**

Not classified based on available information.

### **Components:**

#### **Benzyl alcohol:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

---

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Effects on fertility : Test Type: Three-generation study  
Species: Rat  
Application Route: Oral  
General Toxicity F1: NOAEL: 0.015 mg/kg body weight  
Fertility: NOAEL: > 0.04 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Species: Cattle  
Application Route: Intramuscular  
General Toxicity - Parent: LOAEL: 0.16  $\mu$ g/kg  
Result: positive  
Remarks: Abortion

Effects on foetal development : Test Type: Development  
Species: Rabbit  
Application Route: Subcutaneous  
Teratogenicity: NOAEL: 0.250  $\mu$ g/kg  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
Teratogenicity: NOAEL: 100  $\mu$ g/kg  
Result: No teratogenic effects

Reproductive toxicity - Assessment : May damage fertility.

### **STOT - single exposure**

Not classified based on available information.

### **Components:**

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Target Organs : Lungs  
Assessment : Causes damage to organs.

### **STOT - repeated exposure**

Not classified based on available information.

### **Components:**

### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Target Organs : Ovary  
Assessment : Causes damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

### Repeated dose toxicity

#### Components:

##### **Benzyl alcohol:**

Species : Rat  
NOAEL : 1.072 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 28 Days  
Method : OECD Test Guideline 412

##### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Species : Rat  
NOAEL : 0.05 mg/kg  
LOAEL : 0.15 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Ovary

Species : Rat  
LOAEL : 0.0125 mg/kg  
Application Route : Subcutaneous  
Exposure time : 30 Days  
Target Organs : Ovary

Species : Monkey  
NOAEL : 0.05 mg/kg  
LOAEL : 0.15 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Heart, Testis

### Aspiration toxicity

Not classified based on available information.

#### Components:

##### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Not applicable

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

---

### Experience with human exposure

#### Components:

#### **Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

General Information : Target Organs: Uterus (including cervix)  
Symptoms: Embryo-foetal toxicity, foetal mortality, menstrual irregularities, miscarriage  
Target Organs: Lungs  
Symptoms: Asthma, bronchospasm

Inhalation : Target Organs: Lungs  
Symptoms: bronchospasm, Asthma  
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.  
Target Organs: Uterus (including cervix)  
Symptoms: Embryo-lethal effects, menstrual irregularities

Skin contact : Target Organs: Lungs  
Symptoms: bronchospasm  
Remarks: Can be absorbed through skin.  
Target Organs: Uterus (including cervix)  
Symptoms: Embryo-lethal effects

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### **Benzyl alcohol:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 230 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 51 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version 3.3      Revision Date: 08.12.2023      SDS Number: 25294-00024      Date of last issue: 30.11.2023  
Date of first issue: 24.10.2014

---

**Sodium [1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ ,5 $\alpha$ ]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

### Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

### 12.2 Persistence and degradability

#### Components:

##### **Benzyl alcohol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 92 - 96 %  
Exposure time: 14 d

### 12.3 Bioaccumulative potential

#### Components:

##### **Benzyl alcohol:**

Partition coefficient: n-octanol/water : log Pow: 1.05

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

### SECTION 14: Transport information

#### 14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 75

If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of H-Statements

H302 : Harmful if swallowed.  
H319 : Causes serious eye irritation.  
H332 : Harmful if inhaled.  
H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H360F : May damage fertility.  
H370 : Causes damage to organs.  
H372 : Causes damage to organs through prolonged or repeated exposure.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Eye Irrit. : Eye irritation  
Repr. : Reproductive toxicity  
Resp. Sens. : Respiratory sensitisation  
STOT RE : Specific target organ toxicity - repeated exposure  
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure-Activity Relationship

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.11.2023
3.3	08.12.2023	25294-00024	Date of first issue: 24.10.2014

---

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN